Navigation Links
Director Garrett A. Garrettson, Ph.D. to Step Down After Decade-Long Service
Date:8/7/2014

MOUNTAIN VIEW, Calif., Aug. 7, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that, after more than a decade of service, Garrett A. Garrettson has resigned his seat on the IRIDEX Board of Directors.

President and CEO Will Moore said, "Garry's insight and guidance on matters of technology, capital markets and corporate governance were a constant and steadying force through some very eventful years at IRIDEX. On behalf of all the shareholders, we are grateful for his decade of commitment and oversight and wish him well as he sets off on his next set of ventures."

Dr. Garrettson served as a director of the Company since 2004 and served as Lead Independent Director and then Chairman of the Company's Board of Directors from January 2008 to September 2010. Dr. Garrettson is currently a principal of daVinci Capital Group, a private equity fund, and of G. Garrettson Consulting.

About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The company maintains a deep commitment to the success of its customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through both direct and independent sales forces and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the company's website at http://www.iridex.com.

Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to changes at the Company as a result of Garry Garrettson's resignation, the Company's commitments to its customers and the technological superiority of the Company's products. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in the Company's Quarterly Report on Form 10-Q and the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardinal Health Board of Directors Approves Quarterly Dividend, Authorizes Increase to Share Repurchase Program, Announces Board Leadership Changes
2. Rock Creek Pharmaceuticals Expands The Board with the Appointment of Two Independent Directors
3. BioSpecifics Technologies Corp. Announces Appointment of Max Link, Ph.D. to Board of Directors
4. invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens
5. invendo medical Appoints Nachum (Homi) Shamir To The Companys Board Of Directors
6. Abide Therapeutics Appoints Nancy Thornberry to Board of Directors
7. IGI Laboratories, Inc. Announces Change To Its Board Of Directors
8. Craig Mundie Joins RainTree Oncology Board of Directors
9. BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors
10. Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board
11. WaferGen Bio-Systems Announces Appointment of Ivan Trifunovich as Chairman of the Board; Joel Kanter to Serve as Lead Independent Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Mar 29, 2017 Research and Markets has ... Forecast to 2023" report to their offering. ... The ablation device global market ... $20,995.5 million by 2023. Ablation is the minimally ... purposes, from cancerous or diseased tissue removal, to the removal of ...
(Date:3/29/2017)... , March 29, 2017   Dynatronics ... today the appointment of Cynthia L. McHenry ... will be responsible for leading Dynatronics manufacturing, distribution, ... will report to Dynatronics, CEO Kelvyn H. ... concludes an extensive search process conducted by the ...
(Date:3/29/2017)... FinancialBuzz.com News Commentary  ... Data published in a research report by Grand View Research, ... of USD 55.8 billion by 2025. The projection takes into consideration the ... and a more open approach towards cannabis products around the world. In ... , North Dakota , Ohio , ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... ... scientific laboratories. The assembly protocols involve many repetitive steps and often scientists require ... which enables the high-throughput needed, and results in a lower error rate and ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... of Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who ... at Intercontinental Time Square, New York. , The program will be led ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education ... quality, the field must first improve teacher preparation program design. It then asserts ... and that decades of input- and outcome-based research has failed to improve teacher ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield Advisors ... brings his extensive knowledge of appraisals, property values, ad valorem taxation, and government ... valuation industry for more than 40 years. , “Ruel is a great addition ...
(Date:3/28/2017)... ... 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid ... Thyroid Secret. Dr. Wentz talked about journey and research recently on a blog and ... NOT the only solution to deal with thyroid disease. , Dr. Wentz completed ...
Breaking Medicine News(10 mins):